| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Research and development | 17,938 | 32,198 | 47,754 | 45,617 |
| General and administrative | 10,331 | 13,394 | 14,260 | 15,022 |
| Total operating expenses | 28,269 | 45,592 | 62,014 | 60,639 |
| Loss from operations | -28,269 | -45,592 | -62,014 | -60,639 |
| Interest and other income (expense), net | 2,783 | 3,101 | 5,128 | 5,653 |
| Interest expense | 815 | 809 | 877 | 868 |
| Net loss | -26,301 | -43,300 | -57,763 | -55,854 |
| Net unrealized gain (loss) on short-term investments | 35 | -160 | 1,465 | -128 |
| Comprehensive loss | -26,266 | -43,460 | -56,298 | -55,982 |
| Net loss per share - basic (usd per share) | -0.43 | -0.71 | -0.95 | -0.92 |
| Net loss per share - diluted (usd per share) | -0.43 | -0.71 | -0.95 | -0.92 |
| Shares used in computing net loss per share - basic (in shares) | 61,406,475 | 61,386,183 | 60,730,935 | 60,382,796 |
| Shares used in computing net loss per share - diluted (in shares) | 61,406,475 | 61,386,183 | 60,730,935 | 60,382,796 |
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)